News | December 23, 2022
Strides Pharma Global receives AUD 94 mn for sale of Australia's operations
The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument
The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument
The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.
They will commercialize molnupiravir in the international markets
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
The company expects revenue growth of 10-15 per cent in the US
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru
Subscribe To Our Newsletter & Stay Updated
